Consensus DNA Vaccine for CCHFV Envelope Glycoprotein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) as current therapies are limited, and supportive care is often the only option for treatment.
Innovation Solution
A composition comprising a nucleic acid sequence that encodes a synthetic consensus CCHFV envelope glycoprotein immunogen is provided, which can be administered to induce an immune response against CCHFV, potentially offering prophylactic and therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If supportive care is provided for CCHFV infection, then patient management is simplified, but treatment effectiveness and survival rate improve significantly
Solution Approach 1:
The patent applies preliminary action by developing a vaccine that prevents CCHFV infection before it occurs. The DNA vaccine expresses viral envelope glycoproteins that stimulate protective immune responses, including neutralizing antibodies and T cell activation, thereby preventing the disease rather than treating it after infection occurs.
Solution Approach 2:
The patent converts the harmful viral envelope glycoproteins into beneficial vaccine antigens. By using synthetic consensus sequences of these glycoproteins (particularly the S protein) as vaccine immunogens, the harmful viral components are transformed into protective elements that elicit immunity without causing disease.
2Reliability
If a DNA vaccine expressing CCHFV envelope glycoprotein is administered, then protective immune response is generated, but manufacturing and sequence optimization complexity increases
Solution Approach 1:
The patent applies parameter changes by optimizing the DNA vaccine sequence through codon optimization for human cells, adjusting GC content, and modifying the nucleotide sequence to enhance expression and immunogenicity. The synthetic consensus sequence is designed with specific parameters (GC content, codon usage) to maximize vaccine effectiveness while simplifying manufacturing.
Solution Approach 2:
The patent achieves universality by designing a consensus vaccine sequence that represents multiple CCHFV strains. The synthetic consensus envelope glycoprotein sequence incorporates amino acids conserved across different viral strains, creating a universal vaccine that provides protective immunity against various CCHFV variants without requiring strain-specific formulations.
3Adaptability or versatility
If synthetic consensus CCHFV envelope glycoprotein sequence is used, then broad viral strain coverage is achieved, but sequence design and validation complexity increases
Solution Approach 1:
The patent applies parameter changes by analyzing amino acid sequences from multiple CCHFV strains and identifying conserved regions. The synthetic consensus sequence is designed with specific parameters (amino acid conservation, glycosylation sites, epitope regions) to ensure broad viral strain coverage while maintaining manageable sequence design complexity through systematic approach.
Solution Approach 2:
The patent applies segmentation by dividing the viral envelope glycoprotein into functional regions (signal peptide, transmembrane domain, extracellular domains, glycosylation sites). This segmentation allows systematic design and validation of the consensus sequence, focusing on critical functional elements while simplifying the overall sequence design process.
Data Source
AI summary
Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Crimean-Congo hemorrhagic fever virus (CCHFV) antigens. Immunomodulatory methods and methods of inducing an immune response against CCHFV are disclosed. CCHFV glycoprotein immunogens are disclosed.